Unlock Strategic Intelligence with Fundz

Access exclusive insights on funding rounds, strategic shifts with FundzWatch™, Family Offices, and more — faster than your competitors.

Micreos Secures €32 Million For Its Endolysin-Based Platform As Sustainable Alternative To Antibiotics

09/30/21, 9:30 AM

Location

the hague

Money raised

€32 million

Dutch biotechnology company Micreos announced it has secured another €32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria. This funding round will help Micreos accelerate its clinical development programs for atopic dermatitis, diabetic (MRSA) wounds and bloodstream infections, based on its pharmaceutical lead compounds, XZ.700 and SP.800.

🔒 Strategic shifts and deeper insights are available for this company. Unlock full access to view hidden updates, executive moves, and more.

Company Info

Company

Micreos.

Location

the hague, south holland, netherlands

Additional Info

Micreos develops new biological therapies based on targeted killing of only unwanted bacteria, set to replace antibiotics in a wide range of applications, The company is viewed as a global leader in this field. Its proprietary endolysin technology has been created together with the Swiss Federal Technology Institute, ETH Zurich. Headquartered in The Hague, The Netherlands, Micreos runs its technology center in Zurich, with operations in the Netherlands and the USA. Under the Gladskin brand, Micreos has launched several endolysin-based OTC products for people with inflammatory skin conditions caused or aggravated by S. aureus, including acne, eczema and rosacea, and helped hundreds of thousands of people. SOURCE Micreos

Track Every New Funding Round — Before Anyone Else

This is just a small preview. Unlock access to thousands more filtered results — updated in real-time by stage, region, investor & more.

Trusted by sales, BD, and investment teams at Oracle, HubSpot, Affinity, and more.